Health‐related quality of life and treatment effects in patients with well‐differentiated gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta‐analysis. (30th August 2021)

• Record Type: Journal Article
• Authors: Ronde, Elsa M.; Heidsma, Charlotte M.; Eskes, Anne M.; Schopman, Josefine E.; Nieveen van Dijkum, Elisabeth J. M.
• Is Part Of: European journal of cancer care. Volume 30:Number 6(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-08-30
• Subjects: adverse drug events -- neoplasms -- neuroendocrine tumour -- quality of life -- treatment -- treatment outcome; Cancer -- Nursing -- Periodicals; 616.994
• DOI: 10.1111/ecc.13504
• Languages: English
• ISSNs: 0961-5423

Abstract

Abstract: Introduction: Gastroenteropancreatic neuroendocrine neoplasms (GEPNENs) are often diagnosed in an advanced stage. As the optimal sequence of therapy remains largely unclear, all treatment‐related outcomes, including health‐related quality of life (HRQoL) prospects, should be assessed according to patients' preferences. Methods: A targeted search was performed in PubMed and EMBASE to identify studies on treatment effect and HRQoL, measured using the EORTC QLQ‐C30 tool, in patients with advanced, well‐differentiated GEPNENs. Study quality was assessed, and meta‐analyses were performed for global health status/QOL and tumour response. Results: The search yielded 1, 322 records, and 20 studies were included, examining somatostatin analogues (SSA), peptide receptor radionuclide therapies (PRRT), chemotherapy, SSA‐based combination therapies, and targeted therapies. Global HRQoL was stable, and rates for disease stabilisation were moderate to high across all treatments. Meta‐analyses for global health status/QOL after SSA treatment were not significant (mean difference: –0.3 [95% CI: −1.3 to 0.7]). The highest pooled overall tumour response rate was 33% (95% CI: 24–45%) for PRRT. The highest pooled clinical benefit rate was 94% (95% CI: 65–99%) for chemotherapy. Conclusion: All treatments appeared beneficial for disease stabilisation while maintaining stable global health status/QOL. High‐quality HRQoL reporting was lacking. HRQoL should be a central outcome next to well‐established outcomes.